<DOC>
	<DOCNO>NCT00019214</DOCNO>
	<brief_summary>RATIONALE : Vaccines make white blood cell treat antigen may make body build immune response kill melanoma cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Combining vaccine therapy interleukin-2 may kill melanoma cell . PURPOSE : This phase I/II trial study side effect well give vaccine therapy interleukin-2 work compare vaccine therapy alone treat patient metastatic melanoma respond previous therapy .</brief_summary>
	<brief_title>Vaccine Therapy With Without Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate toxicity , immunologic reactivity , possible therapeutic efficacy immunization dendritic cell present MART-1 gp100 melanoma antigens without interleukin-2 patient metastatic melanoma . OUTLINE : This dose-escalation study dendritic cell pulse MART-1 gp100 antigen . Patients receive vaccination dendritic cell pulse MART-1 gp100 antigen , either intralymphatically every 4 week 2 dos , IV every 3 week 4 dos . Some patient also receive interleukin-2 subcutaneously IV , 3-5 day , begin 24 hour immunization . Cohorts 2-9 patient receive escalate dos pulse dendritic cell IV maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Subsequent cohort receive cell without interleukin-2 . One cohort may expand 15 patient determine accuracy immunologic response vaccine . One cohort 11 patient receive cell intralymphatically without interleukin-2 every 3-4 week 2 course . Patients stable disease achieve minor , mixed , partial response may retreat . Patients stable respond disease undergo second course vaccination . Patients complete treatment vaccine alone stable disease , progressive disease , disease progression response , partial response improvement may receive 2 additional course . PROJECTED ACCRUAL : A total 10-42 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma fail standard effective therapy Measurable evaluable disease HLAA2 positive PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 8.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL AST/ALT le 4 time upper limit normal Negative hepatitis B surface antigen No coagulation disorder Renal : Creatinine great 1.6 mg/dL OR Creatinine clearance great 75 mL/min Cardiovascular : No major cardiovascular disease Pulmonary : No major respiratory disease Other : No major immunological disease No penicillin allergy HIV negative No active systemic infection Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy At least 4 week since prior steroid therapy recover Radiotherapy Not specify Surgery Not specify Other More 4 week since prior therapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>recurrent melanoma</keyword>
</DOC>